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Abstract
Background: Hepatitis B virus is one of the most important blood born viruses. Although the sensitivity of
screening tests has been considerably increased, transmission may still occur due to window period or occult
hepatitis B infections (OBIs). This study was aimed at evaluating the prevalence of the anti-HBc and identifying the
HBV DNA in HBsAg negative blood donors.
Methods: The Blood samples from 2031 HBsAg-negative blood donors were divided into three aliquots and tested
for anti-HBc, anti-HBs and HBV DNA. Serologic screening including anti-HBc and anti-HBs was performed. As a
confirmatory test, all positive results for anti-HBc were retested with another kit. Two positive results were
considered for anti-HBc positivity. All HBsAg negative selected donations were tested by PCR assay on pooled
specimens (five samples per pool), plasma samples found to be HBsAg negative but anti-HBc positive were selected
for a single-unit specimen Real-Time assay.
Results: The study population had a mean age of 33.25 ± 10.09 years were mainly composed of males (94.8 %). The
seroprevalance rate was 4.9 % for Anti-HBc and 31.9 % for HBsAb. The majority (58.6 %) of Anti-HBc positive cases
were regular blood donors with 42–49 years being the largest age group (41.4 %). Neither individual NAT nor
pooled NAT test detected any HBV DNA.
Conclusion: However, Screening of anti-HBc Ab is proposed as a method to identify previous contact with HBV,
but there is controversy in literature data regarding the cost-benefit of exclusion of positive anti-HBc Ab in blood
donors. Our data does not suggest HBc-Ab test as a screening tool in the study setting.
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Background
Blood and blood products are inseparable part of the
treatment in many medical settings. Therefore, the avail-
ability of adequate safe blood and blood products re-
mains a major concern in health care system and
transfusion practice. The limited data from WHO Global
Database on blood safety indicates around 92 million
blood donations worldwide and more than 9 million
blood transfusions in ninety countries, annually [1].
Currently, Iran has achieved 100 % voluntary non-
remunerated blood donation, and in 2011 about 2
million blood donations were recorded [2]. For a variety
of the most important infectious agents that are trans-
mitted via blood transfusion such as HBV, HCV, HIV
and syphilis, screening tests are performed as routine
practice. However, despite considerable improvements in
eligibility criteria for blood donation and development of
more advanced screening methods, transfusion transmit-
ted infectious agents like hepatitis B virus still present as
a threat for blood safety. Currently About 0.2 % of do-
nated blood from apparently healthy donors in Iran is
diagnosed as HBsAg-positive and is hence discarded [2].
This phenomenon is observed on different scales in
other blood services across the world [3]. By perceiving
the HBV host interaction, it was shown that even HBsAg
negative individuals might be infected and there is a
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chance of transmission especially upon transfusion.
Thus, despite all efforts including the use of a highly
sensitive HBsAg test, transmission may still occur from
apparently healthy blood donors. This may be attributed
to the inability of the screening tests to detect HBsAg
during a window period or as a result of the occult HBV
infections (OBIs). OBI arises when the HBV DNA is de-
tected, while HBsAg remaining undetectable. In about
20 % of cases the only positive marker is HBV DNA but
in other situations anti-HBc or anti-HBs could be de-
tected as well. Several factors may be involved in OBI,
including mutated HBsAg, low level expression of
HBsAg or entrapment of antigen in the circulatory im-
mune complexes [4–6]. The prevalence of hepatitis B
virus infection in the population and the sensitivity of la-
boratory methods could affect the reported prevalence
rates of OBI [7]. Some studies have suggested that in
HBsAg negative and anti-HBc positive cases, there is a
possibility of low level infectious HBV viremia. This
study was conducted in order to determine the fre-
quency of anti-HBc and HBV DNA in blood donors with
undetectable HBsAg. Since HBsAg test is the only
screening method in Iranian blood donation centres, the
necessity for supplemantary screening tests such as anti-
HBc or NAT test were studied as well.
Methods
During the time frame of the present study (2013),
86,182 blood donations from voluntary blood donors in
two main blood collection centres (Kermanshah and
Ahwaz) were evaluated for HBsAg. HBsAg positive do-
nors were excluded and HBsAg negative donors were
considered for inclusion in the study. The donors were
categorized as first-time, repeated and regular donors on
the basis of blood donation history and according to the
definition by Iranian Blood Transfusion Organization
(IBTO). Based on the calculated sample size, a total of
2031 HBsAg negative donations were randomly selected.
The samples were centrifuged and plasma was separated.
Each sample was divided into three aliquots and stored
at −70 °C for further processing. The samples screened
for anti-HBc, anti-HBs and HBV DNA according to
standard procedures carried out in the laboratories of
IBTO. This study was approved by the IBTO Ethics
Committee. Anti-HBc positive and negative subjects
were further studied in terms of demographic variables
such as age, gender, occupational status, in addition to
blood donation and vaccination history.
ELISA tests
Serologic screening including anti-HBc (Cut-off
= (NC + PC)/5; OD = 450 nm; positivity of > 1.1) and
anti-HBs were tested (DIA.PRO Diagnostic Bioprobes
s.r.l, Milano, Italy) according to the manufacturer’s
instructions. All positive results for anti-HBc were
retested with another kit (IgM-IgG-HBc Ab DADE
Behring, Germany). Two positive results were consid-
ered for anti-HBc positivity.
Detection of HBV DNA
All HBsAg negative selected donations were tested by
PCR assay on pooled specimens (five samples per pool)
plasma samples found to be HBsAg negative but anti-
HBc positive were selected for a single-unit specimen
Real-Time assay. HBV-DNA was extracted from 200 μl
of plasma by using the QIAamp DSP virus purification
kit (Qiagen GmbH, Hilden, Germany) and detected with
a commercial PCR kit (Qiagen GmbH, 4 Hilden,
Germany) on a Light Cycler instrument (Roche
Diagnostics-version2) according to the protocols recom-
mended by the manufacturers. In each run, we used
plasma negative and positive samples to prevent false
positive and negative results. Also, to verify both steps
DNA extraction and inhibition in PCR reaction, internal
control was used for all samples. The lower detection
limit for Real-Time PCR in this study was 9 IU/mL.
Also, for confirmation of the results obtained, another
sensitive in house HBV-DNA NAT was used that the
sensitivity of the assay for HBV-DNA was 30 IU/ml. The
analytical sensitivity of the PCR test was assessed using
triplicate analysis of 10-fold serial dilutions of the world
health organization (WHO) international standard for
HBV (NIBSC; Hertfordshire, United Kingdom). The
95 % detection limits of the assays were calculated by
probit analysis. The lower limit of detection of the PCR
was 20 IU/ml. Clinical specificity was determined using
100 blood donor samples that were negative for HBV
DNA, resulting in a clinical specificity of 100 %. The
clinical sensitivity of the PCR assay was determined
using a low-titer dilution series of an HBV genotype D
specimen. HBV DNA was diluted to concentrations of
150, 125, 100, 75, 40, 30, 20 and 10 IU/ml. The lower
limit of detection of the PCR was 30 IU/ml. For detect-
ing all of the HBV genotypes, WHO International Refer-
ence Panel, containing hepatitis B virus genotypes A–G
was used for assays.
Results
During the study period, 86,182 units of blood from vol-
unteer donors were collected. A total of 102 (0.12 %)
blood donors were HBsAg positive and therefore were
not further evaluated. As shown in flow-chart, the re-
sults of this study were obtained from three laboratory
tests: Anti-HBc, Anti-HBs and NAT (Fig. 1). Anti-HBc
positivity rate was 4.9 % (99/2031). The study population
consisted of 1928 males (94.92 %) and 103 females
(5.08 %), between 18 and 65 years with a mean age of
33.25 ± 10.09. The anti-HBs positivity rate was 31.9 %
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(647/2031) among the entire study population. It is re-
ported a vaccination history in 591 (29 %) of blood do-
nors of which 380 (64.3 %) were Anti-HBs positive. The
majority (98.9 %) of Anti-HBc positive donors were male
and mainly from the 42–49 year age group (41.4 %).
There were statistically significant differences between
Anti-HBc positive and negative donors in age groups
(p = 0.001). In anti-HBc positive subjects, 15.2 % (15/
99) were anti-HBs negative. Fifty-eight (58.6 %) of
anti-HBc positive individuals were regular blood
donor. statistically significant relationship was ob-
served between anti-HBc positivity and regular blood
donation (P = 0.001). All of the 99 anti-HBc positive
samples that were tested by individual nucleic acid test
were HBV DNA negative. Moreover, pooled NAT (five
samples per pool) on the HBsAg negative samples (2031)
did not show HBV DNA in any sample (Table 1).
Discussion
Detection of hepatitis B virus in blood donors with
Australia antigen test (HBsAg test) began in 1970. In
respect to the above mentioned issue, Iranian Blood
Transfusion Organization since its establishment in 1974
has screened all donated blood for hepatitis B virus.
In 1979, the prevalence of HBsAg among voluntary
blood donors in Iran was reported to be 3.4 % [8]. How-
ever this rate has been dramatically decreased over the
past 30–35 years and the current prevalence rate of
HBsAg among voluntary blood donors has reached to
0.2 % [2], with variations between different regions. Fur-
thermore, HBV prevalence rate of 2.14 % has been re-
ported in the general population [9]. This decrease
could be attributed to the improvement in donor
selection procedures along with the application of
community based preventive measures such as integra-
tion of HBV vaccination in Expanded Programme on
Immunization (EPI) since 1993, increased community
health education, and development of highly sensitive
screening tests. Owing to these safety strategies post
transfusion hepatitis is now a very rare event. No evi-
dence about the incidence of post transfusion hepatitis B
in Iran has been found. In a review article published by
H. Rezvan et al. the prevalence of HBSAg in β thalas-
semia major and haemodialysis patients (as multitrans-
fused patients) has been reported around the general
population [10]. Even though, there were no evidence
that they are actually infected via blood transfusions. So
that, we are not capable to find any evidence in case of
post transfusion hepatits B prevalence in Iran. Neverthe-
less, circulating HBV DNA in HBsAg negative blood do-
nors (occult HBV infection) can be a threat to blood
safety. Therefore, performing HBsAg test does not elim-
inate the risk of HBV transmission to blood recipients
completely. It has been reported that OBI is associated
Fig. 1 Flow chart of laboratory process in HBsAg-negative
blood donations
Table 1 Serological prevalence and other characteristics among blood donors
Serological profile Total
Characteristics HBsAb + HBsAb + HBsAb – HBsAb –
HBcAb + HBcAb – HBcAb + HBcAb –
84 (4.1 %) 563 (27.76 %) 15 (0.74 %) 1369 (67.4 %) 2031
Mean age ± SD 42.6 ± 9.95 35.3 ± 10.4 39.6 ± 11.8 34.6 ± 8.9 -
Donor type First time 16 (19 %) 82 (14.6 %) 7 (46.7 %) 300 (22 %) 405
Repeated 16 (19 %) 128 (22.7 %) 2 (13.3 %) 290 (21.1 %) 436
Regular 52 (62 %) 353 (62.7 %) 6 (40 %) 779 (56.9 %) 1190
Vaccination history 30/84 (35.7 %) 350/563 (62.2 %) 4/15 (26.7 %) 207/1365 (15.2 %) 591
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with the presence of anti-HBc or anti-HBs. Even more,
in some cases neither anti-HBc can be detected nor
anti-HBs [11]. Given the above considerations, it is pro-
posed that implementing genomic screening (NAT) in
high and low prevalence countries could lead to substan-
tial safety in view of window period and OBI related risk
of transfusion transmitted Hepatitis B. The detection
limit of NAT ranges from 1:1000 to 1:50,000 depending
on the epidemiology and sensitivity of the assay as de-
scribed by Alain [3].
The rate of positive serologic test results for anti-HBc
was found to be 4.9 % in the present study and isolated
anti-HBc were found in 15 cases (0.74 %). In the litera-
ture, anti-HBc prevalence rates between 2.1 and 11.5 %
has been reported among Iranian blood donors (Table 2),
and the prevalence of anti-HBc in Iranian general popu-
lation has been reported to be 16.4 % [22]. Thus, our re-
sults are in accordance with the literature data. The
slight differences between our results and the previous
ones may be described by many factors such as different
sample size, laboratory methods, and different epidemio-
logical conditions.
Several conditions may result in positive isolated anti-
HBc in an apparently healthy blood donor. One possibil-
ity is recovered past HBV infection, which did not apply
to our donors as they had no history of hepatitis. Never-
theless, hepatitis B infections are sometimes asymptom-
atic and patients do not manifest jaundice or any other
symptoms/signs. Another possibility is false-positive re-
sults due to be poor specificity of the test [23]. To
minimize false-positive results, we repeated the test with
the same method, and all reactive samples were positive
in repeated measurements. Finally, there is risk of HBV
transmission in pre-seroconversion widow period, i.e. a
period that infected blood donors have not been
seroconvert yet, hence HBsAg and anti-HBc are nega-
tive. Therefore, in addition to anti-HBc positive cases, all
HBsAg negative samples were also evaluated by mini-
pool nucleic acid testing. Our study demonstrated an
anti-HBs prevalence rate of 31.9 % (647/2031) in HBsAg
negative blood donors. Specimens from 84 blood donors
were positive for both anti-HBs and anti-HBc. Thus, 563
blood donors were positive for anti-HBs alone. Regard-
ing the vaccination history of 591 cases, it appears that
in spite of vaccination, 28 subjects could not produce
the HBsAb response.
Considering the fact that concurrent detection of anti-
HBc and anti-HBs might be assessed as an indicator of
past exposure and recovery, it can be inferred from our
results that 4.1 % of our donors had a history of infec-
tion, and were immune due to previous exposure/infec-
tion. There is evidence that HBV DNA can be detected
even in anti-HBs positive blood donors [24, 25]. Thus it
has been suggested that the presence of anti-HBs anti-
body does not rule out the possibility of HBV transmis-
sion. In this study, no HBV DNA in the serum samples
of HBsAg negative blood donors was detected regardless
of positive or negative anti-HBc and anti-HBs test re-
sults. A review of the similar published studies in Iranian
blood donors shows different statistics. According to a
review of 11 published articles, the prevalence of HBV
DNA in HBsAg negative/anti-HBc positive blood donors
varied from 0 to 50 % (Table 2). These studies have been
carried out in different geographical areas and also have
used different PCR methods such as qualitative, real
time and nested PCR. Our study as well as three other
studies suggests the absence of OBI in the studied blood
donors. Therefore it may be suggested that these results
may be influenced by methods and/or laboratory
conditions (sampling condition, testing methods and
Table 2 Reported prevalence of Anti-HBc, HBV DNA and OBI in HBsAg Negative blood donors based on some published studies in
Iran
Reference City Number of donors (HBsAg-) Anti-HBc+ n (%) HBV DNA+/Anti-HBc+ n (%) OBI n (%)
Sofian et al. [12] Arak 531 11(2.1 %) 0/11 (0 %) 0
Shahabi et al. a Mashhad 5059 432(8.5 %) 0/60 (0 %) 0
AminiKafi-abad et al. [13] Tehran 2000 230 (11.5) 0/230 (0 %) 0
Khamesipour et al. [14] Rasht 2041 78 (3.8 %) 1/78 (1.3 %) 1 (0.05 %)
Pourazar et al. [15] Isfahan 545 43 (8 %) 5/43 (11.62 %) 5 (0.92 %)
Behbahani et al. [16] Shiraz 2000 131 (6.55 %) 16/131 (12.2 %) 16 (0.8 %)
Arababadi et al. [17] a Rafsanjan 3700 352 (9.51 %) 57/352 (16.1 %) 57 (1.54 %)
Jafarzadeh et al. [18] Rafsanjan 270 14 (5.18 %) 4/14 (28.57 %) 4 (1.48 %)
Delavari et al. [19] Kerman 1525 121 (8 %) 36/121 (29.7 %) 36 (2.36 %)
Vaezjalali et al. [20] Tehran 1000 80 (8 %) 40/80 (50 %) 40 (4 %)
Alizadeh et al. [21] Tehran 5000 499 (9.8 %) 2/499 (0.4 %) 2 (0.04 %)
Total – 23,671 1991 (8.4 %) 161 (9.9 %) 161 (0.7 %)
a Article published in Persian
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equipment) used by different researchers. Vaezjalali et al,
who reported the highest frequency, claimed improved
accuracy of HBV DNA detection through the use of a
homemade nested PCR technique with at least two dif-
ferent sets of primers in their study. In a study con-
ducted earlier by Shahabi et al (article in Persian) this
method has been used as well. In the mentioned article,
there was no evidence of HBV DNA in 60 samples.
The results of similar studies on the frequency of
HBV-DNA positivity in HBsAg negative, anti-HBc
positive blood donors in other countries show great
variation. The frequency was reported 0 % in Turkey
and Greece [26–28], 1.25 % in Saudi Arabia [29], 1.59 %
in Germany [23], 4.86 % in Italy [30], 7.5 % in India [31],
17.2 % in Egypt [32], 38 % in Japan [33] and 90.5 % in
Sudan [34].
Differences in the frequencies of occult HBV infection
in different studies could be related to the endemicity of
HBV infection, geographical variations, the sensitivity of
the screening tests being used to detect HBV DNA and
other viral markers, sample size, power of the study,
composition of study population and so on.
Evidence shows that anti-HBc testing has only a little
effect on the blood safety. However, the use of individual
NAT test can improve the HBV related blood safety. In
spite of introducing the individual NAT test, transfusion
centres cannot bypass the serological tests and various
combinations of serology and NAT are implemented in
different countries [3]. Currently, about 27 countries in
the world have implemented NAT for hepatitis B virus
screening in blood donors as a mandatory or voluntary
approach [35]. High coverage of HBV vaccination in the
early infantile period (around 97 %) was achieved and
consequently a marked decrease in the HBV prevalence
among general population was reported. In addition,
vaccination in the health care workers has been imple-
mented since 1993 and mass vaccination for adolescents
who was born from 1989 to 1992 was also performed to
extend the immunity to larger group of young popula-
tion. Moreover, a series of studies on the general popula-
tion have shown that the efficacy of hepatitis B vaccine
has been more than 80 % [36, 37]. The combined effect
of vaccine and improvement on public health status re-
sulted change in the HBV epidemic and Iran now is in a
low-intermediate state. So that the epidemiological fea-
ture of virus in Iran might be presented as a describing
factor to decrease the necessity of NAT test on Iranian
blood donors.
Conclusions
Occult HBV infection is a complex issue especially given
the fact that many circumstances and conditions may in-
fluence the clinical and laboratory findings. In order to
detect HBV-DNA in very low levels, it is necessary to
use a highly sensitive technique.
In this study, HBV-DNA in anti-HBc seropositive
blood donors could not be detected. Therefore, based on
our data it is not suggested to screen anti-HBc or HBV
NAT in Iranian blood donors. On the other hand, differ-
ent rates of occult HBV infection in blood donors are re-
ported across the country. In addition it should be
considered that anti-HBc screening of the blood donors
will lead to the loss of a significant number of donors.
For example, in our experience, screening the donors for
anti-HBc could result in approximately 5 % loss in blood
donations, without significant evidence that such condi-
tion could affect the blood safety. Therefore, the decision
on implementing the anti-HBc and HBV NAT should be
based on more comprehensive, multicenter studies to
perceive the actual amount of occult HBV infection in
the general population and blood donors.
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